Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

tiragolumab (RG6058)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

TIGIT inhibitor

Related drugs:

PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	atezolizumab + RG6058 Sensitive: B - Late Trials atezolizumab + RG6058 Sensitive : B	atezolizumab + RG6058 Sensitive: B - Late Trials atezolizumab + RG6058 Sensitive : B
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria atezolizumab + RG6058 Sensitive : C2	atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria atezolizumab + RG6058 Sensitive : C2
PD-L1 expression	Esophageal Cancer	PD-L1 expression	Esophageal Cancer	atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria atezolizumab + RG6058 Sensitive : C2	atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria atezolizumab + RG6058 Sensitive : C2